NASDAQ: ATYR - aTyr Pharma, Inc.

Altı ay boyunca karlılık: +77.84%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı aTyr Pharma, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında aTyr Pharma, Inc.

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

daha fazla ayrıntı
The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2015-05-07
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.atyrpharma.com
Цена ао 3.24
Günlük fiyat değişimi: -3.99% (3.26)
Haftalık fiyat değişimi: -14.95% (3.68)
Aylık fiyat değişimi: -19.12% (3.87)
3 ayda fiyat değişimi: -16.31% (3.74)
Altı ayda fiyat değişimi: +77.84% (1.76)
Yılbaşından bu yana fiyat değişimi: -8.48% (3.42)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 1143.94 1
P/BV 3.85 4
P/E 0 0
EV/EBITDA -4.08 0
Toplam: 3.25

Yeterlik

İsim Anlam Seviye
ROA, % -58.88 0
ROE, % -79.69 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.2001 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -97.76 0
karlılık Ebitda, % 353.22 10
karlılık EPS, % -41.45 0
Toplam: 6
Daha fazla ayrıntı

ETFPaylaşmak, %Yıllık karlılık, %Temettüler, %
iShares Micro-Cap ETF 0.03199 17.09 1.54048
0.0317.091.54



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Sanjay S. Shukla M.D., M.S. President, CEO & Director 1972 (53 yıl)
Ms. Jill M. Broadfoot Chief Financial Officer 1962 (63 yıl)
Ms. Nancy E. Denyes Krueger General Counsel & Corporate Secretary 1968 (57 yıllar)
Xiang-Lei Yang Ph.D. Founder
Dr. Jayant Aphale MBA, Ph.D. Vice President of Technical Operations 1960 (65 yıllar)
Ms. Ashlee Dunston Director of Investor Relations & Corporate Communications
Mr. Peter Villiger Vice President of Corporate Development
Ms. Danielle Campbell VP of Human Resource
Dr. Leslie Nangle Ph.D. Vice President of Research
Dr. Ying J. Buechler Ph.D. Executive Director of Biologics Development & Manufacturing

Adres: United States, San Diego, 10240 Sorrento Valley Road - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.atyrpharma.com